Predicting Sustained Benefit From Tirzepatide in SURPASS-4: Who Benefits and Why?
- PMID: 40971612
- DOI: 10.2337/dbi25-0033
Predicting Sustained Benefit From Tirzepatide in SURPASS-4: Who Benefits and Why?
Comment on
-
Predictors of Initial and Sustained Glycemic and Weight Response to Tirzepatide: A Post Hoc Analysis of SURPASS-4.Diabetes. 2025 Oct 1;74(10):1850-1862. doi: 10.2337/db25-0276. Diabetes. 2025. PMID: 40633089 Free PMC article. Clinical Trial.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
